FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

MICHELLE RUDEK-RENAUT

Research Profile

Chemicals & Drugs

Disorders

Neoplasms

Concepts & Ideas

Procedures

Living Beings

Mouse

Co-author Network

Publications

TOP 3
MICHELLE RUDEK-RENAUT; Vered Stearns; Stanley P Watkins; Laurie A Wright; Ming Zhao; Deborah K Armstrong; Roisin M Connolly; Nancy E Davidson; John H Fetting; Elizabeth Garrett-Mayer; Janelle M Hoskins; Stacie C Jeter; Howard L McLeod; Antonio C Wolff
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
Nilofer S Azad; Michael A Carducci; Arvind Dasari; Luis Alberto Diaz; Ross C Donehower; Manuel Hidalgo; Daniel Laheru; Martine McManus; Kevin Quackenbush; MICHELLE RUDEK-RENAUT; Gretchen E Taylor; John J Wright; Ming Zhao; John Arcaroli; Wells A Messersmith
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Daniel Laheru; DUNG LE; Sheila Linden; Florencia McAllister; RAJESH KUMAR NV; MICHELLE RUDEK-RENAUT; Preeti Shah; Dongweon Song; Gretchen Taylor; Ming Zhao; Ross C Donehower; Howard Goldsweig; Antonio Jimeno; Manuel Hidalgo
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of MICHELLE RUDEK-RENAUT (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: MICHELLE RUDEK-RENAUT; Vered Stearns; Stanley P Watkins; Laurie A Wright; Ming Zhao; Deborah K Armstrong; Roisin M Connolly; Nancy E Davidson; John H Fetting; Elizabeth Garrett-Mayer; Janelle M Hoskins; Stacie C Jeter; Howard L McLeod; Antonio C Wolff
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
Breast cancer research and treatment 2013;139(1):135-43.
2013: Nilofer S Azad; Michael A Carducci; Arvind Dasari; Luis Alberto Diaz; Ross C Donehower; Manuel Hidalgo; Daniel Laheru; Martine McManus; Kevin Quackenbush; MICHELLE RUDEK-RENAUT; Gretchen E Taylor; John J Wright; Ming Zhao; John Arcaroli; Wells A Messersmith
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Investigational new drugs 2013;31(2):345-54.
2012: Daniel Laheru; DUNG LE; Sheila Linden; Florencia McAllister; RAJESH KUMAR NV; MICHELLE RUDEK-RENAUT; Preeti Shah; Dongweon Song; Gretchen Taylor; Ming Zhao; Ross C Donehower; Howard Goldsweig; Antonio Jimeno; Manuel Hidalgo
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
Investigational new drugs 2012;30(6):2391-9.
2012: Maria Cristina Villarroel; John J Wright; Linping Xu; Keith William Pratz; B Douglas Smith; MICHELLE RUDEK-RENAUT
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients.
Investigational new drugs 2012;30(6):2096-102.
2012: Judith E Karp; Mark Levis; Karen Mackey; A MICHAEL MCDEVITT; Megan Othus; Keith William Pratz; MICHELLE RUDEK-RENAUT; Margaret Mary Showel; B Douglas Smith; John J Wright; Hetty Carraway; Kathleen Shannon Dorcy; L Austin Doyle; D Michelle Drye; Elihu H Estey; Elizabeth Garrett-Mayer; Douglas E Gladstone; Steven D Gore; Jacqueline M Greer; John M Pagel
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Haematologica 2012;97(11):1736-42.
2012: Jill Gilbert; Sara Bienvenu; Arlene A Forastiere; Michaela J Higgins; MICHELLE RUDEK-RENAUT; Nancy Tsottles; Richard L Wahl; Ming Zhao; Muhammad A Chaudhry; Maura L Gillison
A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(6):1735-42.
2011: MICHELLE RUDEK-RENAUT; Jane B Alavi; Joy D Fisher; Tom Mikkelsen; L Burt Nabors; Pamela New; Surasak Phuphanich; Steven Piantadosi; Stuart A Grossman
Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas.
Journal of neuro-oncology 2011;105(2):375-81.
2011: Constance L Monitto; MICHELLE RUDEK-RENAUT; CAROL THOMPSON; Elizabeth White; Sabine Kost-Byerly; Carlton K K Lee; Myron Yaster
The optimal dose of prophylactic intravenous naloxone in ameliorating opioid-induced side effects in children receiving intravenous patient-controlled analgesia morphine for moderate to severe pain: a dose finding study.
Anesthesia and analgesia 2011;113(4):834-42.
2011: Mary Cianfrocca; Bruce J Dezube; Susan E Krown; Sandra Lee; MICHELLE RUDEK-RENAUT; Jamie H Von Roenn; Joseph A Sparano
Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial.
Cancer chemotherapy and pharmacology 2011;68(4):827-33.
2011: Colin D Weekes; Sharyn D Baker; Ross C Donehower; Manuel Hidalgo; Antonio Jimeno; Daniel Laheru; KATHLEEN MURPHY; Sujatha Nallapareddy; Alexis Norris-Kirby; MICHELLE RUDEK-RENAUT; Wells A Messersmith
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Investigational new drugs 2011;29(5):1057-65.
2011: Savita Bisht; Toby Cornish; Mehtab A Khan; Debomoy Lahiri; Anirban Maitra; Amarnath Maitra; Masamichi Mizuma; Balmiki Ray; MICHELLE RUDEK-RENAUT; Ming Zhao; Haibo Bai; Mena Bekhit; Robert A Anders
A polymeric nanoparticle formulation of curcumin (NanoCurc™) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation.
Laboratory investigation; a journal of technical methods and pathology 2011;91(9):1383-95.
2011: MICHELLE RUDEK-RENAUT; Charles Flexner; Richard F Ambinder
Use of antineoplastic agents in patients with cancer who have HIV/AIDS.
The lancet oncology 2011;12(9):905-12.
2011: Betty M. Tyler; Ananth Vellimana; Scott Wadsworth; Robert T Wicks; Ming Zhao; Hiep Do; Gary L Gallia; Khan Li; Vivek Mehta; Violette Recinos; Joel Rosenblatt; MICHELLE RUDEK-RENAUT; I-Mei Siu; Henry Brem
Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats.
Neuro-oncology 2011;13(7):700-9.
2011: Paula M Fracasso; Kerry J Williams; Ronald C Chen; Joel Picus; Cynthia X Ma; Matthew J Ellis; Benjamin R Tan; Timothy J Pluard; Douglas R Adkins; Michael J Naughton; Janet S Rader; Matthew A Arquette; James W Fleshman; Allison N Creekmore; Sherry A Goodner; Lisa P Wright; Zhanfang Guo; Christine E Ryan; Yu Tao; Eliane M Soares; Shi-Rong Cai; Li Lin; Janet Dancey; MICHELLE RUDEK-RENAUT; Howard L McLeod; Helen Piwnica-Worms
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
Cancer chemotherapy and pharmacology 2011;67(6):1225-37.
2011: Roisin M Connolly; MICHELLE RUDEK-RENAUT; Elizabeth Garrett-Mayer; Stacie C Jeter; Michele G Donehower; Laurie A Wright; Ming Zhao; John H Fetting; Leisha A Emens; Vered Stearns; Nancy E Davidson; Sharyn D Baker; Antonio C Wolff
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.
Breast cancer research and treatment 2011;127(1):153-62.
2011: Judith E Karp; B Douglas Smith; Linda M. Resar; Jacqueline M Greer; Amanda Blackford; Ming Zhao; Dwella Moton-Nelson; Katrina Alino; Mark Levis; Steven D Gore; Biju Joseph; Hetty Carraway; A MICHAEL MCDEVITT; Lorena Bagain; Karen Mackey; Janet Briel; L Austin Doyle; John J Wright; MICHELLE RUDEK-RENAUT
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
Blood 2011;117(12):3302-10.
2011: Camilo Rojas; M Stathis; Michael Polydefkis; MICHELLE RUDEK-RENAUT; Ming Zhao; Gigi Ebenezer; Barbara Slusher
Glutamate carboxypeptidase activity in human skin biopsies as a pharmacodynamic marker for clinical studies.
Journal of translational medicine 2011;9():27.
2011: B Douglas Smith; Richard J Jones; Eunpi Cho; Jeanne Kowalski; Judith E Karp; Steven D Gore; Milada Vala; Brooke Meade; Sharyn D Baker; Ming Zhao; Steven Piantadosi; Zhe Zhang; Gideon Blumenthal; Erica D Warlick; Robert A Brodsky; Anthony Murgo; MICHELLE RUDEK-RENAUT; William Matsui
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.
Leukemia research 2011;35(1):87-94.
2010: Wells A Messersmith; Antonio Jimeno; Heather A Jacene; Ming Zhao; Piotr Kulesza; Daniel Laheru; Yasmin Kahn; Alexander Spira; Janet Dancey; Christine A Iacobuzio-Donahue; Ross C Donehower; Michael A Carducci; MICHELLE RUDEK-RENAUT; Manuel Hidalgo
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Clinical colorectal cancer 2010;9(5):297-304.
2010: Lie Li; Ming Zhao; Fariba Navid; Keith William Pratz; B Douglas Smith; MICHELLE RUDEK-RENAUT; Sharyn D Baker
Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(29):3033-8.
2010: Ryan M Franke; Michael A Carducci; MICHELLE RUDEK-RENAUT; Sharyn D Baker; Alex Sparreboom
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4562-7.
2010: I Garrido-Laguna; Aik Choon Tan; M Uson; M Angenendt; Wen W Ma; M C Villaroel; Ming Zhao; RAJESH KUMAR NV; Antonio Jimeno; Ross C Donehower; Christine A Iacobuzio-Donahue; M Barrett; MICHELLE RUDEK-RENAUT; Belen Rubio-Viqueira; Daniel Laheru; Manuel Hidalgo
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.
British journal of cancer 2010;103(5):649-55.
2010: Savita Bisht; Masamichi Mizuma; Georg Feldmann; Niki A Ottenhof; Seung-Mo Hong; Dipankar Pramanik; Venugopal Chenna; Collins A Karikari; Rajni Sharma; Michael Goggins; MICHELLE RUDEK-RENAUT; Rajani Ravi; Amarnath Maitra; Anirban Maitra
Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer.
Molecular cancer therapeutics 2010;9(8):2255-64.
2010: Keith William Pratz; E Cho; Mark Levis; Judith E Karp; Steven D Gore; A MICHAEL MCDEVITT; A Stine; Ming Zhao; Sharyn D Baker; Michael A Carducci; John J Wright; MICHELLE RUDEK-RENAUT; B Douglas Smith
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Leukemia 2010;24(8):1437-44.
2010: Hans-Joerg Hammers; Hendrik Verheul; Brenda Salumbides; Rajni Sharma; MICHELLE RUDEK-RENAUT; Janneke Jaspers; Preeti Shah; Leigh Ellis; Li Shen; Silvia Paesante; Karl Dykema; Kyle A Furge; Bin Tean Teh; GEORGES NETTO; Roberto Pili
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Molecular cancer therapeutics 2010;9(6):1525-35.
2010: Andrew J Armstrong; GEORGES NETTO; MICHELLE RUDEK-RENAUT; Susan Halabi; David P Wood Jr; Patricia A Creel; Kelly Mundy; S Lindsay Davis; Ting Wang; Roula Albadine; Luciana Schultz; Alan W Partin; Antonio Jimeno; Helen Fedor; Phillip G Febbo; Daniel J George; Robin Gurganus; Angelo M DeMarzo; Michael A Carducci
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(11):3057-66.
2010: Sarah Reinhardt; Ming Zhao; Aleksander Mnatsakanyan; Linping Xu; Rebecca M Ricklis; Alice Chen; Judith E Karp; MICHELLE RUDEK-RENAUT
A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS.
Journal of pharmaceutical and biomedical analysis 2010;52(1):122-8.
2010: Wenyue Sun; Yan Liu; Chad A Glazer; Chunbo Shao; Sheetal Bhan; SEMRA DEMOKAN; Ming Zhao; MICHELLE RUDEK-RENAUT; Patrick K Ha; Joseph A Califano
TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(3):857-66.
2010: Wen Wee Ma; JOSEPH HERMAN; Antonio Jimeno; Daniel Laheru; Wells A Messersmith; Christopher L Wolfgang; John L Cameron; Timothy M Pawlik; Ross C Donehower; MICHELLE RUDEK-RENAUT; Manuel Hidalgo
A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer.
Translational oncology 2010;3(6):373-9.
2010: Soner Altiok; Heather Mezzadra; Sanjay B Jagannath; Nancy Tsottles; MICHELLE RUDEK-RENAUT; Nadia Abdallah; David Berman; Arlene A Forastiere; Michael K Gibson
A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer.
International journal of oncology 2010;36(1):19-27.
2010: Apostolia-Maria Tsimberidou; MICHELLE RUDEK-RENAUT; David Hong; Chaan S Ng; Jessica Blair; Howard Goldsweig; Razelle Kurzrock
Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.
Cancer chemotherapy and pharmacology 2010;65(2):235-41.
2009: Jianqing Lin; Jill Gilbert; MICHELLE RUDEK-RENAUT; James Zwiebel; Steven D Gore; Anchalee Jiemjit; Ming Zhao; Sharyn D Baker; Richard F Ambinder; James G Herman; Ross C Donehower; Michael A Carducci
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):6241-9.
2009: Shuiying Hu; Zhaoyuan Chen; Ryan Franke; Shelley Orwick; Ming Zhao; MICHELLE RUDEK-RENAUT; Alex Sparreboom; Sharyn D Baker
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):6062-9.
2009: A Jimeno; A Chan; George Cusatis; X Zhang; J Wheelhouse; A Solomon; F Chan; Ming Zhao; Stephen Cosenza; M V Ramana Reddy; MICHELLE RUDEK-RENAUT; Piotr Kulesza; Ross C Donehower; E P Reddy; Manuel Hidalgo
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Oncogene 2009;28(4):610-8.
2009: David Durrant; Frank Corwin; Daniele Simoni; Ming Zhao; MICHELLE RUDEK-RENAUT; Fadi N Salloum; Rakesh C Kukreja; Panos P Fatouros; Ray M Lee
cis-3, 4', 5-Trimethoxy-3'-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion.
Cancer chemotherapy and pharmacology 2009;63(2):191-200.
2008: Savita Bisht; Georg Feldmann; Jan-Bart M Koorstra; Michael Mullendore; Hector Alvarez; Collins Karikari; MICHELLE RUDEK-RENAUT; Carlton K K Lee; Amarnath Maitra; Anirban Maitra
In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities.
Molecular cancer therapeutics 2008;7(12):3878-88.
2008: Antonio Jimeno; Jing Li; Wells A Messersmith; Daniel Laheru; MICHELLE RUDEK-RENAUT; Manoj Maniar; Manuel Hidalgo; Sharyn D Baker; Ross C Donehower
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(34):5504-10.
2008: Daniel Laheru; Gary Croghan; Ronald Bukowski; MICHELLE RUDEK-RENAUT; Wells A Messersmith; Charles Erlichman; Robert Pelley; Antonio Jimeno; Ross C Donehower; Joseph Boni; Richat Abbas; Patricia Martins; Charles Zacharchuk; Manuel Hidalgo
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5602-9.
2008: Antonio Jimeno; MICHELLE RUDEK-RENAUT; Peter Kulesza; Wen W Ma; Jenna Wheelhouse; Anna Howard; Yasmin Khan; Ming Zhao; Heather A Jacene; Wells A Messersmith; Daniel Laheru; Ross C Donehower; Elizabeth Garrett-Mayer; Sharyn D Baker; Manuel Hidalgo
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4172-9.
2008: Ming Zhao; Ping He; Linping Xu; Manuel Hidalgo; Daniel Laheru; MICHELLE RUDEK-RENAUT
Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;869(1-2):142-5.
2008: Antonio Jimeno; MICHELLE RUDEK-RENAUT; W. PURCELL; Daniel Laheru; Wells A Messersmith; Janet Dancey; Michael A Carducci; Sharyn D Baker; Manuel Hidalgo; Ross C Donehower
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Cancer chemotherapy and pharmacology 2008;61(3):423-33.
2007: Jing Li; Ming Zhao; Antonio Jimeno; Ping He; M V Ramana Reddy; Manuel Hidalgo; Ross C Donehower; MICHELLE RUDEK-RENAUT
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;856(1-2):198-204.
2007: Xiaosong Zhang; Ming Zhao; MICHELLE RUDEK-RENAUT; Ping He; Bert Vogelstein
Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of DMXAA in human and mouse plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;852(1-2):217-22.
2007: Ming Zhao; MICHELLE RUDEK-RENAUT; Ping He; Frank-Thorsten Hafner; Martin Radtke; John J Wright; B Douglas Smith; Wells A Messersmith; Manuel Hidalgo; Sharyn D Baker
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;846(1-2):1-7.
2007: Ming Zhao; MICHELLE RUDEK-RENAUT; Aleksandr Mnasakanyan; Carol Hartke; Roberto Pili; Sharyn D Baker
A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma.
Journal of pharmaceutical and biomedical analysis 2007;43(2):784-7.
2007: Wells A Messersmith; MICHELLE RUDEK-RENAUT; Sharyn D Baker; Ming Zhao; Connie Collins; A Dimitrios Colevas; Ross C Donehower; Michael A Carducci; Antonio C Wolff
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2007;43(1):78-86.
2006: MICHELLE RUDEK-RENAUT; Ming Zhao; Ping He; Wells A Messersmith; Sharyn D Baker
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ABT-751, ABT-751 glucuronide, and ABT-751 sulfate in human plasma for clinical pharmacology studies.
Journal of pharmaceutical and biomedical analysis 2006;42(2):253-60.
2006: Steven D Gore; Stephen B Baylin; Elizabeth Sugar; Hetty Carraway; Carole B Miller; Michael A Carducci; Michael R Grever; Oliver Galm; Tianna Dauses; Judith E Karp; MICHELLE RUDEK-RENAUT; Ming Zhao; B Douglas Smith; Jasper Manning; Anchalee Jiemjit; George J Dover; Abbie Mays; James Zwiebel; Anthony J Murgo; Li-Jun Weng; James G Herman
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Cancer research 2006;66(12):6361-9.
2005: MICHELLE RUDEK-RENAUT; Ming Zhao; Ping He; Yelena Zabelina; Runyan Jin; Wells A Messersmith; Antonio C Wolff; Sharyn D Baker
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005;828(1-2):41-54.
2005: MICHELLE RUDEK-RENAUT; Ming Zhao; Nicola F Smith; Robert W Robey; Ping He; Gurulingappa Hallur; Saeed R Khan; Manuel Hidalgo; Antonio Jimeno; A Dimitrios Colevas; Wells A Messersmith; Antonio C Wolff; Sharyn D Baker
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(23):8503-11.
2005: Nielka P H van Erp; Sharyn D Baker; Ming Zhao; MICHELLE RUDEK-RENAUT; Henk-Jan Guchelaar; J W R Nortier; Alex Sparreboom; Hans Gelderblom
Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7800-6.
2005: MICHELLE RUDEK-RENAUT; Ming Zhao; Ping He; Carol Hartke; Jill Gilbert; Steven D Gore; Michael A Carducci; Sharyn D Baker
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3906-11.
2005: MICHELLE RUDEK-RENAUT; Carol Hartke; Yelena Zabelina; Ming Zhao; Pamela New; Sharyn D Baker
A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection.
Journal of pharmaceutical and biomedical analysis 2005;37(4):751-6.
2005: Ming Zhao; MICHELLE RUDEK-RENAUT; Ping He; B Douglas Smith; Sharyn D Baker
Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry.
Analytical biochemistry 2005;337(1):143-8.
2005: Elizabeth Dees; Sharyn D Baker; Seamus O'Reilly; MICHELLE RUDEK-RENAUT; Susan B Davidson; Cheryl Aylesworth; Kathy Elza-Brown; Michael A Carducci; Ross C Donehower
A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):664-71.
2004: Ming Zhao; MICHELLE RUDEK-RENAUT; Ping He; Carol Hartke; Steven D Gore; Michael A Carducci; Sharyn D Baker
Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;813(1-2):81-8.
2004: MICHELLE RUDEK-RENAUT; Yelena Zabelina; Ming Zhao; Antonio C Wolff; Sharyn D Baker
A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV.
Biomedical chromatography : BMC 2004;18(5):282-7.
2004: Hallur Gurulingappa; Maria L Amador; Ming Zhao; MICHELLE RUDEK-RENAUT; Manuel Hidalgo; Saeed R Khan
Synthesis and antitumor evaluation of benzoylphenylurea analogs.
Bioorganic & medicinal chemistry letters 2004;14(9):2213-6.
2004: MICHELLE RUDEK-RENAUT; Alex Sparreboom; Elizabeth Garrett-Mayer; Deborah K Armstrong; Antonio C Wolff; Jaap Verweij; Sharyn D Baker
Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1170-8.
2004: MICHELLE RUDEK-RENAUT; Ross C Donehower; Paul Statkevich; Vijay K Batra; David L Cutler; Sharyn D Baker
Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.
Pharmacotherapy 2004;24(1):16-25.
2003: Ming Zhao; Yelena Zabelina; MICHELLE RUDEK-RENAUT; Antonio C Wolff; Sharyn D Baker
A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS.
Journal of pharmaceutical and biomedical analysis 2003;33(4):725-33.
2003: MICHELLE RUDEK-RENAUT; Kenneth S. Bauer; Richard M Lush; Sherman F Stinson; Adrian M Senderowicz; Donna Headlee; Arbuck Susan; Michael C Cox; Anthony J Murgo; Edward A Sausville; William D Figg
Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
The Annals of pharmacotherapy 2003;37(10):1369-74.
2003: MICHELLE RUDEK-RENAUT; Jürgen Venitz; Yuichi Ando; Eddie Reed; James M Pluda; William D Figg
Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies.
Journal of clinical pharmacology 2003;43(10):1124-35.
2003: Ming Zhao; Ping He; MICHELLE RUDEK-RENAUT; Manuel Hidalgo; Sharyn D Baker
Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;793(2):413-20.
2002: W. PURCELL; MICHELLE RUDEK-RENAUT; Manuel Hidalgo
Development of matrix metalloproteinase inhibitors in cancer therapy.
Hematology/oncology clinics of North America 2002;16(5):1189-227.
2002: MICHELLE RUDEK-RENAUT; Jürgen Venitz; William D Figg
Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy?
Pharmacotherapy 2002;22(6):705-20.
2002: Mary Cianfrocca; Timothy P Cooley; Jeannette Y Lee; MICHELLE RUDEK-RENAUT; David T Scadden; Lee Ratner; James M Pluda; William D Figg; Susan E Krown; Bruce J Dezube
Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):153-9.
2001: MICHELLE RUDEK-RENAUT; McDonald Horne; William D Figg; William Dahut; V Dyer; James M Pluda; Eddie Reed
Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.
American journal of hematology 2001;67(1):51-3.
2001: J V Ghate; Maria L Turner; MICHELLE RUDEK-RENAUT; William D Figg; William Dahut; V Dyer; James M Pluda; Eddie Reed
Drug-induced lupus associated with COL-3: report of 3 cases.
Archives of dermatology 2001;137(4):471-4.
2001: MICHELLE RUDEK-RENAUT; William D Figg; V Dyer; William Dahut; Maria L Turner; Seth M Steinberg; David J Liewehr; David R Kohler; James M Pluda; Eddie Reed
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):584-92.
2000: Kenneth S. Bauer; Richard M Lush; MICHELLE RUDEK-RENAUT; C Shih; Edward A Sausville; William D Figg
A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva.
Biomedical chromatography : BMC 2000;14(5):338-43.
2000: MICHELLE RUDEK-RENAUT; C L March; Kenneth S. Bauer; James M Pluda; William D Figg
High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma.
Journal of pharmaceutical and biomedical analysis 2000;22(6):1003-14.
2000: Erwin A Kruger; Paul H Duray; M G Tsokos; David J Venzon; Steven Libutti; Shannon C Dixon; MICHELLE RUDEK-RENAUT; James M Pluda; Carmen J Allegra; William D Figg
Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.
Biochemical and biophysical research communications 2000;268(1):183-91.